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Highlights  
 HPV16 and HPV18 E6 DNA loads increase with the grade of cervical lesions 
 HPV18 viral load is less preformant than HPV16 viral load for idenfying CIN2+  
 HPV16 viral load may be considered as a triage test in HPV16/HIV-coinfected 
women 
 
 
ABSTRACT 
Background: African women living with HIV (WLHIV) are at high risk of cervical cancer but 
rarely adequately screened.  Better strategies enabling identification of WLHIV with high-
grade cervical intraepithelial lesions (CIN2+) are required. 
Objectives: To  investigate the diagnostic value of HPV16 and HPV18 viral loads in a cohort 
of African WLHIV. 
Design: HPV16 and HPV18 viral loads were determined by quantitation of the E6 gene DNA 
by real-time PCR in cervical specimens collected at baseline and endline (16 months) from 
245 African WLHIV positive for HPV16 or/and HPV18. Cervical biopsies were graded using 
the histopathological CIN classification.    
Results: Women with CIN2+ had higher viral load for HPV16 (p<0.0001) or HPV18 (p=0.03) 
than those without CIN2+. HPV16 viral load 3.59 log copies/1,000 cells detected CIN2+ with 
sensitivity and specificity of 93.5% (95%CI: 81.7 to 98.3%) and 74.1% (95%CI: 66.3 to 
80.6%), respectively, whereas HPV18 viral load 1.63 log copies/1,000 cells detected CIN2+ 
with sensitivity and specificity of  59.1% (95%CI: 38.7 to 76.7%) and  66.9% (95%CI: 58.8 to 
74.1%), respectively. A high baseline HPV16 viral load was significantly associated with 
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persistence of, or progression to CIN2+ at endline; these findings were not observed for 
HPV18. 
Conclusions: HPV16 viral load is a powerful marker of CIN2+ in African WLHIV. HPV18 viral 
load is of lower diagnostic value in this population. 
Keywords: HPV16; HPV18; viral load; cervical intraepithelial neoplasia 
1. Background 
Cervical cancer is the fourth most common cancer in women worldwide and the most 
common cancer and main cause of cancer mortality in women living in low income and 
developing countries, particularly in sub-Saharan Africa [1-2]. Virtually all cases of cervical 
cancer result from a persistent infection with high-risk human papillomaviruses (HR-HPV), 
HPV16 and HPV18 being associated with over 70% invasive cervical cancer cases [3].  
Women living with HIV (WLHIV) have an increased risk of persistent HR-HPV infection and 
development of precancerous and cancerous lesions [4], and preventative strategies 
targeting this highly exposed population are required. In women currently not eligible for HPV 
vaccination, prevention of cervical cancer relies on the detection and treatment of 
precancerous lesions. In most sub-Saharan African countries, access to cervical cancer 
screening by cytological examination of cervical cells (pap test) is limited by a lack of 
resources [5]. Visual inspection with acetic acid and Lugol’s iodine (VIA/VILI) performed by 
trained physicians or nurses is more widely used in sub-Saharan African countries, but the 
diagnostic performance of this simple cost-effective screening method varies across studies 
and is very dependent on the level of training of the observer [6-7]. Detection of HR-HPV 
DNA in cervical specimens has proven high sensitivity for identifying women with cervical 
precancerous/cancerous lesions [8]. Simple and affordable HPV DNA tests may be used for 
cervical cancer screening in resource-poor settings [9-10]. We have shown that this 
approach was effective for detecting high-grade cervical intraepithelial neoplasia (CIN) 
among WLHIV in Burkina Faso and South Africa [11]. However, in this highly-infected 
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population, the high sensitivity of HR-HPV DNA testing for detection of high-grade cervical 
lesions is counterbalanced by a relative low specificity [11-12], and a triage test would be 
required to determine which women may benefit from the more expensive and less easily 
accessible colposcopy referral. It has been reported that HPV16 DNA levels in cervical 
samples increase with lesion severity and thus, measurement of HPV16 viral load might be 
considered as a triage tool for identifying women at risk of high-grade CIN [13-20]. Data on 
HPV18 viral load are more sparse, and the association with cervical lesion severity is less 
clear [18, 20, 21-24].  
2. Objectives 
The objective of the present study was to investigate the diagnostic value of HPV16 and 
HPV18 viral loads in a cohort of WLHIV enrolled in a prospective evaluation of cervical 
cancer screening approaches in sub-Saharan Africa.   
3. Study design 
3.1. Study population 
The HARP (HPV in Africa Research partnership) study enrolled women with HIV-1 infection 
aged 15-49 in Ouagadougou, Burkina Faso, and Johannesburg, South Africa, for a 
prospective study over 18 months. The HARP study methodology has been described in 
detail elsewhere [11, 25]. In brief, at enrolment (baseline) and at the follow-up visit scheduled 
at month (M) 18 (endline) and that actually occurred at a median (IQR) 16 (15.5-16.8) 
months later, women benefited from cervical screening using cytology, VIA/VILI, HR-HPV 
DNA screening using digene HC2 test (at baseline) or careHPV tests (at endline) (both 
Qiagen, Gaithersburg, MD) and colposcopic examination. Systematic 4-quadrant cervical 
biopsies, including directed biopsy of any suspicious lesions, were obtained for participants 
who had abnormalities detected by cytology, VIA/VILI or colposcopy, or who had a positive 
HR-HPV DNA test. Local histological findings using the CIN classification were reviewed by 
the HARP Endpoint Committee consisting of five pathologists for consensus classification of 
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the cervical lesions [26]. In addition, HPV DNA detection and typing using the INNO-LiPA 
HPV genotyping Extra assay (Fujirebio, Courtaboeuf, France) was performed as previously 
described [27] for all women enrolled in the HARP study at baseline and endline. CD4+ cell 
counts were measured by flow cytometry using the FACScount system (Beckton Dickinson, 
Franklin Lakes, NJ, USA). The present study was conducted among the sub-group of HARP 
participants who were positive for HPV16 or/and HPV18 DNA at enrolment and/or at endline. 
We intended to treat all women with CIN2+ lesions, but this was not possible for all women 
during the follow-up period for a variety of reasons, mostly women not attending their 
gynaecological clinic appointments in South Africa. Written informed consent was obtained 
from all participants. Ethical clearance was obtained from the Ministry of Health of Burkina 
Faso, the University of Witwatersrand in Johannesburg, and the London School of Hygiene & 
Tropical Medicine.  
3.2. HPV 16 and HPV18 viral loads  
Determination of HPV16 and HPV18 viral loads were performed as previously described [16, 
24] on the DNA extracts used for the genotyping assay. In brief, viral loads were measured 
by quantitation of HPV16 and HPV18 E6 gene DNA by real-time PCR. Standard curves were 
obtained by serial dilution of pBR322-HPV16 and pBR322-HPV18 plasmids. Whole cell DNA 
was measured by quantitation of the GAPDH gene using a human DNA standard curve. 
SiHa (1-2 copies of HPV16 genome per cell), Caski (>500 copies of HPV16 genomes per 
cell) and HeLa (multiple copies of HPV18 genome) cell lines were used as controls. The 
lower limit of quantitation for E6 DNA for both HPV types was calculated to be 0.05 
copies/1,000 cells. 
3.3. Data analysis 
Women without CIN or with CIN1 were categorized as <CIN2, and women with CIN2, CIN3 
and higher grade lesions were categorized as CIN2+.  
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Results were expressed as the log number of copies of E6 DNA per 1,000 cells. Values of 
E6 DNA loads under the lower limit of quantitation (-1.30 log copies/1,000 cells) were set at 
this value.  
For each genotype, viral loads were compared among women with no CIN, CIN1, CIN2 and 
CIN3 using the Kruskal-Wallis test and between <CIN2 and CIN2+ using the Mann-Whitney 
U test. Receiver operating characteristic (ROC) curve analyses with calculation of area under 
the curve (AUC) were used to evaluate the ability of HPV16 and HPV18 E6 viral loads to 
separate women with CIN2+ from <CIN2. For association of persistence or progression of 
lesions between baseline and endline with E6 DNA levels, logistic regression was used to 
calculate odds ratios (OR) with 95% confidence intervals (95%CI). Data were analysed using 
the XLSTAT2016 software (Addinsoft, Paris, France). 
4. Results 
Among the 1238 WLHIV enrolled in the HARP study who were tested for HPV detection and 
genotyping, 245 (19.8%) were positive for HPV16 or HPV18 at baseline and/or endline. 
These women had a median (IQR) age of 34 (30-41) years, had a median (IQR) CD4+ T-cell 
count of 417 (324-557) cells/µL, and 158 of them (64.5%) were on antiretroviral therapy 
(ART).  
At baseline, 122 and 103 of these women were positive for HPV16 and HPV18, respectively, 
25 of them being positive for both HPV16 and HPV18. At endline, 78 and 66 women were 
positive for HPV16 and HPV18, respectively, 11 of them being positive for both HPV16 and 
HPV18. Among the 122 women positive for HPV16 at baseline, 50 remained positive 
(persistence) and 72 became negative (clearance) at endline, whereas among the 123 
women negative for HPV16 at baseline, 25 acquired an incident HPV16 infection. Similarly, 
among the 103 women positive for HPV18 at baseline, 41 showed persistence and 62 
showed clearance, whereas among the 142 women negative for HPV18 at baseline, 25 
acquired an incident HPV18 infection. 
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Overall, 68% of participants at baseline and 65.4% at endline were co-infected with one or 
more HR-HPV types other than HPV16 or HPV18, the most prevalent types being HPV52 
(25.0%), HPV51 (17.0%), and HPV35 (16.5%) 
E6 viral loads for each HPV type according to the histological grades are shown in Table 1. 
E6 DNA levels increased with histological grade and women with CIN2+ had significantly 
higher levels of E6 than those without CIN2 (<CIN2). Within each CIN category, absolute 
values of E6 DNA loads were higher for HPV16 than for HPV18.  
The ROC curve analysis indicated a better performance of HPV16 E6 DNA load 
(AUC=0.877) compared to the HPV18 E6 DNA load (AUC=0.640) for the diagnosis of CIN2+ 
(Fig. 1). The best performance in terms of sensitivity and specificity was observed for a cutoff 
HPV16 E6 DNA load of 3.59 log DNA copies/1,000 cells and a cutoff HPV18 E6 DNA load of 
1.63 log DNA copies/1,000 cells (Table 2). Therefore, E6 DNA levels equal or higher than 
these values for each genotype were considered as ‘high’ viral loads in subsequent 
analyses. For these cutoff values, sensitivity, specificity, positive and negative predictive 
values were higher for HPV16 viral load than for HPV18 viral load (Table 2). 
As shown in Table 3, there was no significant difference between HPV16 or HPV18 viral 
loads and CD4+ cell count levels. Women treated with ART had lower HPV16 but not HPV18 
viral loads than untreated women. HPV16 and HPV18 viral loads were higher in single 
infections than in multiple HR-HPV infections. 
As shown in Table 4, a high HPV16 viral load at baseline was associated with persistence of 
untreated CIN2+ or progression from <CIN2 to CIN2+ ; these findings were not observed for 
HPV18. Overall, among women infected with HPV16, those who remained <CIN2 between 
baseline and endline had a median (IQR) baseline viral load of 1.55 (-1.30 to 3.50) log DNA 
copies/1,000 cells, whereas those showing persistence of CIN2+ or progression from <CIN2 
to CIN2+ had a higher viral load of 5.13 (4.49 to 5.67) log DNA copies/1,000 cells (p=0.001). 
Notably, 4 women had a histological diagnosis of <CIN2 at baseline (1 CIN-negative, 3 CIN1) 
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associated to a high viral load (4.25 to 8.21 log DNA copies/1,000 cells) and all had a 
diagnosis of incident CIN2+ at endline. Among women infected with HPV18, those who 
remained <CIN2 between baseline and endline had a median (IQR) baseline viral load of 
1.48 (-1.30 to 2.83) log DNA copies/1,000 cells, whereas those showing persistence of 
CIN2+ or progression from <CIN2 to CIN2+ had a viral load of 0.37 (-1.30 to 3.08) log DNA 
copies/1,000 cells (p=0.87). 
Between baseline and endline, HPV16 and HPV 18 viral loads increased in women with 
progression to CIN2+ and decreased in women with CIN2+ regression following treatment, 
with DNA level changes >1 log DNA copies/1,000 cells. Viral loads were more stable (<1 log 
DNA copies/1,000 cells) in women with no progression to CIN2+ or with CIN2+ persistence 
(Table 5). 
5. Discussion 
Results obtained in this study indicate that HPV16 viral load, as determined by quantitation of 
E6 DNA, could be a reliable marker of high-grade CIN (CIN2+). HPV16 viral load significantly 
increased with histological grades, and a threshold of 3.59 log DNA copies/1,000 cells 
detected CIN2+ with a sensitivity and specificity of 93.5% and 74.1%, respectively, and a 
high negative predictive value (97.2%). Moreover, among the women initially <CIN2, a high 
HPV16 viral load at baseline was associated with incident CIN2+. The threshold of 3.59 log 
DNA copies/1,000 cells to predict prevalent or incident CIN2+ is in line with the results from 
Saunier et al. [17] who reported that a HPV16 viral load of 22,000 (4.34 log) DNA 
copies/1,000 cells allowed the identification of prevalent CIN2+ with a high specificity, and 
with the results reported by Carcopino et al. [28] who determined that a value of 3.0x106 DNA 
copies/106cells (3.48 log DNA copies/1,000 cells) was a threshold for CIN2+ identification. 
Among women infected with HPV18, an increase in viral load with histological grade was 
also observed, and a HPV18 viral load of 1.63 log DNA copies/1,000 cells identified CIN2+ 
with a sensitivity and specificity of 59.1% and 66.9%, respectively, and a negative predictive 
value of 91.3%. These results indicate that absolute HPV18 viral loads are lower than HPV16 
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viral loads, and that HPV18 viral load is less performant than HPV16 viral load for identifying 
CIN2+, which is supported by the difference in AUC values in the ROC curve analysis. These 
observations are in agreement with previous reports suggesting that HPV18 viral load is low 
in precancerous lesions [20] and has a poor diagnostic performance for detecting CIN2+ [21-
22]. 
This study was conducted among WLHIV and, as expected, high prevalences of HR-HPV 
infection and CIN were observed. However, the majority of these women were not profoundly 
immunosuppressed and we did not observe a significant difference in HPV16 or HPV18 viral 
loads between women with CD4+ T-cell count greater or lower than 350 cells/µL, which was 
the ART eligibility cutoff used in these African countries at the time of the study. We have 
previously reported that ART has an impact on the control of HPV infection and development 
of cervical neoplasia [25], and the finding of lower HPV16 viral loads in women on ART is in 
line with this previous finding. Interestingly, we observed that HPV16 and HPV18 viral loads 
were higher in single HPV16 or HPV18 infections than in multiple HR-HPV infections, 
suggesting an involvement of coinfecting HR-HPV types other than HPV16 and HPV18  in 
the development of CIN. Indeed, we  have reported that HR-HPV types other than 
HPV16/18, notably HPV58, were associated to CIN2+ in these women [29]. The high 
frequency of multiple HR-HPV infection in this population may have limited the performance 
of viral load for identifying CIN2+ in the present study. In particular, the lower performance of 
HPV18 viral load could be due in part to the fact that other HR-HPV types might be involved 
in most CIN2+ associated with a low HPV18 viral load.  
In summary, our findings in a population of WLHIV indicate that, as previously reported for 
HIV-negative women, a high HPV16 viral load represents a useful marker of high-grade 
cervical lesion and might be considered as a triage test for women identified as HPV16-
positive. A standardized commercially available test for HPV16 quantitation, affordable to low 
income countries, should allow to more precisely identify women at risk of cervical 
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carcinoma. On the other hand, HPV18 viral load appears to be of lower diagnostic value in 
this population.  
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Figure legends 
Fig.1. Receiver operator characteristic (ROC) curve analysis of HPV16 (A) and HPV18 (B) 
E6 DNA load for identifying women with high-grade lesions (CIN2+). 
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Table 1. HPV16 and HPV18 E6 DNA loads according to histologic grades of cervical 
lesions. 
 
 
 
 
HPV 
type 
Median (IQR) viral load 
(log E6 DNA copies/1,000 cells) 
 
CIN-
negative 
 
CIN1 
 
CIN2 
 
CIN3 
 
P * 
 
<CIN2 
 
CIN2+ 
 
P ** 
 
HPV16 
 
n = 104 
0.35 
(-1.30 – 
3.65) 
 
n = 45 
2.88 
(0.29 
– 
4.53) 
 
n = 28 
5.14 
(4.25 
– 
6.18) 
 
n = 19 
5.71 
(4.39 
– 
6.37) 
 
 
<0.0001 
 
n = 
149 
0.86 
(-1.30 
– 3.67) 
 
n = 47 
5.44 
(4.29 – 
6.35) 
 
 
<0.0001 
HPV18 n = 93 
-0.92 
(-1.30 – 
2.20) 
n = 48 
1.03 
(-1.30 
– 
2.67) 
n = 17 
1.90 
(-1.18 
– 
3.55) 
n = 5 
4.60 
(-1.30 
– 
5.93) 
 
0.03 
n = 
141 
-0.27 
(-1.30 
– 2.42) 
n = 22 
1.96 
(-1.27 
– 4.23) 
 
0.03 
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Table 2. Performance of HPV16 and HPV18 E6 DNA load threshold values for the 
diagnosis of CIN2+ among 245 African WLHIV.  
 
 
 
Performance indicator 
HPV16 E6 DNA 
3.59 log copies/1,000 cells 
% (95% CI) 
HPV18 E6 DNA 
1.63 log copies/1,000 cells 
% (95% CI) 
Sensitivity  93.5 (81.7 - 98.3) 59.1 (38.7 - 76.7) 
Specificity  74.1 (66.3 - 80.6) 66.9 (58.8 - 74.1) 
PPV  53.8 (46.6 - 60.8) 21.7 (15.9 - 30.6) 
NPV  97.2 (92.2 - 99.1) 91.3 (86.3 - 94.6) 
CI, confidence interval ; PPV, positive predictive value ; NPV, negative predictive 
value 
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Table 3.  HPV16 and HPV18 E6 viral load according to CD4+ cell count, antiretroviral 
therapy (ART) and HR-HPV coinfection. 
 
Parameter HPV16 E6 viral load 
log DNA copies/1,000 cells 
 
P * 
HPV18 E6 viral load 
log DNA copies/1,000 cells 
 
P * 
CD4+ cell count     
     <350 cells/µL 3.24  0.47  
     ≥350 cells/µL 2.37 0.81 0.006 0.78 
ART     
     No 4.12  -0.07  
     Yes 1.90 0.01 0.38 0.68 
HPV coinfection     
     No 3.62  1.88  
     Yes 2.00 0.08 -0.35 0.02 
 * Mann Whitney U test 
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Table 4. Associations of E6 DNA levels of HPV16 and HPV18 measured at baseline 
with evolution of cervical histology over 16 months among WLHIV with absence of 
CIN2+ lesions or untreated CIN2+ lesions at baseline. 
 
 
 
HPV type 
Baseline  
E6 DNA 
level* 
 
No 
progression** 
 
Persistence or 
progression*** 
 
 
OR (95%CI) 
 
 
P 
HPV16 <3.59 18 0   
 3.59 6 11 65.46  
(3.36-1274.90) 
0.006 
HPV18 <1.63 14 4   
 1.63 13 3 0.81 
(0.15-4.32) 
1.0 
CI, confidence interval ; OR, odds ratio 
*3.59 log DNA copies per 1,000 cells and 1.63 log DNA copies per 1,000 cells are 
the thresholds determining high viral loads for HPV16 and HPV18, respectively.  
**<CIN2 at baseline and at endline. 
***Persistence : untreated CIN2+ at baseline and found again at endline ; 
Progression : <CIN2 at baseline and CIN2+ at endline. 
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Table 5. E6 DNA level changes between baseline and endline (16 months later) 
according to the evolution of cervical lesions.  
 E6 DNA level change  
(log DNA copies/1,000 cells) 
Lesion evolution HPV16 HPV18 
No progression -0.51 -0.16 
Persistence +0.74 +0.34 
Progression +1.50 +3.35 
Regression* -3.43 -1.34 
* CIN2+ at baseline and <CIN2 at endline, mostly post-treatment 
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